In a recent transaction, Steven C. Gilman, a director at Vericel Corp (NASDAQ:VCEL), sold 5,834 shares of the company's common stock, netting a total of $265,680. The shares were sold at an average price of $45.54 each. This sale was conducted under an automatic trading plan, known as a Rule 10b5-1 plan, which Gilman had previously set up on May 30, 2024.
On the same day, Gilman also acquired 5,834 shares through the exercise of options at a price of $13.05 per share, amounting to a total transaction value of $76,133. These options were part of a grant that allowed for the purchase of 17,500 shares, which vested in equal monthly installments over one year, starting from May 2, 2018, and were contingent upon Gilman's continued service to the company.
Following these transactions, Gilman's direct ownership in Vericel Corp stands at 11,000 shares of common stock. The company, known for its work in the biological products sector, is incorporated in Michigan and has its business address in Cambridge, Massachusetts.
Investors and followers of Vericel Corp's stock movements should note that these transactions are part of the normal course of business for corporate executives, who may sell or acquire shares for various personal financial reasons. The automatic nature of the sale under a pre-established trading plan provides a structured way of selling shares over time, regardless of any material non-public information they might have, thus complying with insider trading regulations.
In other recent news, Vericel Corporation has seen several significant developments. The U.S. Food and Drug Administration (FDA) approved Vericel's supplemental Biologics License Application for MACI Arthro, an innovative product designed for the arthroscopic treatment of knee cartilage defects. This approval expands Vericel's current offerings and is expected to increase the company's target market within the United States. The FDA also approved the use of NexoBrid for pediatric patients, broadening Vericel's customer base to include around 20 pediatric burn centers across the country.
Several analyst firms have maintained a Buy rating on Vericel's stock, reflecting confidence in the company's direction and the potential impact of its expanded product portfolio on future performance. TD Cowen increased its price target to $60.00, while BTIG and Canaccord Genuity set price targets of $55.00 and $57.00, respectively.
Vericel also reported robust financial results for the second quarter of 2024, achieving a record revenue of nearly $53 million, driven by growth in their MACI product and solid demand for NexoBrid. The company also raised its profitability outlook for the year. These recent developments underscore the ongoing momentum at Vericel Corporation.
InvestingPro Insights
As Vericel Corp (NASDAQ:VCEL) continues to navigate the market, recent data from InvestingPro provides a deeper look into the company's financial health and stock performance. With a market capitalization of $2.28 billion, Vericel is making strides in the biological products sector. The company's revenue has seen a growth of 20.39% over the last twelve months as of Q2 2024, indicating a solid upward trend in its financial performance.
InvestingPro Tips highlight that Vericel is expected to see net income growth this year, which aligns with the company's recent revenue growth. However, it is also trading at a high earnings multiple, with a P/E ratio of 2899.55 for the last twelve months as of Q2 2024. This suggests that the market has high expectations for the company's future earnings. Furthermore, Vericel's stock price movements have been quite volatile, which could be relevant for investors looking for short-term trading opportunities or those with a higher risk tolerance.
On the balance sheet side, Vericel operates with a moderate level of debt and its liquid assets exceed short-term obligations, providing the company with financial flexibility. These insights, along with the fact that analysts predict the company will be profitable this year, may offer investors additional confidence in Vericel's ability to manage its finances and sustain growth.
For those interested in further details and additional insights, InvestingPro offers more tips on Vericel Corp, which can be accessed at the dedicated InvestingPro product page for Vericel. The platform lists a total of 12 InvestingPro Tips for VCEL, providing a comprehensive analysis for investors seeking to make informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.